Lifeline creates subsidiary for breast cancer test
This article was originally published in Clinica
Executive Summary
Reno, Nevada-based Lifeline Biotechnologies has formed a new subsidiary which will focus its efforts on the commercialisation of the firm’s First Warning breast cancer detection system. The creation of the new unit, which will be named First Warning Systems, was prompted when Lifeline filed for patent approval for the technology. The non-imaging system is designed to detect the disease at an early stage by classifying time-related circadian pattern changes in new blood cells supplying a breast cancer. Lifeline claims that the system “records information every five minutes for the duration of the test, collecting over 9,000 data points. The data are then subjected to non-linear algorithmic computer analysis designed to identify abnormalities or disruptions in the normal breast physiology”.